Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
OtherPractice

Update on medical abortion

Ashley Bancsi and Kelly Grindrod
Canadian Family Physician January 2020, 66 (1) 42-44;
Ashley Bancsi
Fourth-year doctoral candidate in pharmacy at the School of Pharmacy at the University of Waterloo in Ontario.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly Grindrod
Associate Professor in the School of Pharmacy at the University of Waterloo and a clinical pharmacist at the Kitchener Downtown Community Health Centre.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • CFPlus
  • eLetters
  • Info & Metrics
  • PDF
Loading

Medical abortion (MA) involves the use of medications to terminate a pregnancy. In Canada, the mifepristone and misoprostol combination is the only Health Canada–approved MA regimen. Abortion is common and 1 in 3 Canadian women will have an abortion in their lifetime.1 In 2018, the approved indication for the mifepristone and misoprostol combination was extended for pregnancies of 49 days’ (7 weeks) to 63 days’ (9 weeks) duration,2 but evidence has shown it is safe and effective for gestational age up to 70 days (10 weeks).3 Canadian health care providers are no longer required to complete a training course before prescribing or dispensing the mifepristone and misoprostol combination, and the cost of the medications is covered in most Canadian jurisdictions, either through public or private health insurance.2

With increased access and clear demand, primary care providers are well positioned to assess and educate patients who wish to have MA. We developed an infographic (Figure 1), also available at CFPlus,* to update health care professionals on MA, as well as to help them support patients. We based the infographic on the Canadian medical abortion guidelines,3 the medication supplement for the guidelines,4 and the medical abortion monograph published by the Canadian Pharmacists Association.5

Figure

How to take MA medications

Mifepristone, a potent antiprogesterone, is taken first as a 200-mg oral tablet, administered with a glass of water. It begins the MA process by causing the endometrial lining to break down and the products of pregnancy to detach from the uterine lining. Mifepristone also promotes uterine contraction, softens the cervix, and sensitizes the myometrium to the effects of misoprostol.

Misoprostol is taken 1 to 2 days later. Patients typically prefer the buccal route, where two 200-μg tablets are placed in each cheek pouch for 30 minutes (2 tablets in the left cheek and 2 tablets in the right cheek for a total of 4 tablets), with any remaining fragments swallowed with water. It can also be administered vaginally or sublingually. Misoprostol is a synthetic prostaglandin that causes the uterus to contract and release the uterine contents.

Prescribing MA

In Canada, MA can be prescribed and dispensed by physicians or nurse practitioners, and dispensed by pharmacists. It is not necessary to supervise administration.

Before a prescription is written, the pregnancy should be confirmed using an in-office pregnancy test and the gestational age calculated using the last menstrual period, a pelvic examination, or an ultrasound. Bloodwork should be completed to determine Rh immune globulin status. If the patient is Rh-negative and at least 49 days pregnant, she should receive an injection of immune globulin 24 hours before starting MA to minimize risk of Rh sensitization for future pregnancies. There is limited evidence for the use of Rh immune globulin before 49 days of pregnancy.3 Finally, an ectopic pregnancy should be ruled out either by ultrasound or clinical symptoms, risk factors, or β-human chorionic gonadotropin levels. A follow-up appointment 7 to 14 days after MA should include a clinical examination, ultrasound, or β-human chorionic gonadotropin measurement to confirm a successful abortion.

Contraindications to MA

Medical abortion has several contraindications, which can be reviewed with the patient using the Medical Abortion Charting Form from the Canadian Abortion Providers Support network (https://www.caps-cpca.ubc.ca/AnnokiUploadAuth.php/e/e0/Canadian_Resource_1_-_Medical_Abortion_Prescriber_Checklist_2018-07-11.pdf). Mifepristone should be avoided in patients with inherited porphyria, as it can cause a porphyria storm, leading to severe abdominal pain, chest pain, vomiting, and confusion.6 Mifepristone is also a potent antiglucocorticoid and should be avoided in patients with chronic adrenal failure or uncontrolled asthma. Patients taking long-term glucocorticoid therapy might require a higher glucocorticoid dose for a week after taking mifepristone. Patients taking anticoagulants, or who have blood disorders or severe anemia (hemoglobin level < 95 g/L), should use MA with caution, as blood loss is expected in MA. Medical abortion will not work for an ectopic pregnancy, and it should not be prescribed if a patient is at increased risk of ectopic pregnancy or has severe abdominal pain or vaginal bleeding. Finally, intrauterine devices increase the likelihood of ectopic pregnancy and should be removed before MA, once an ectopic pregnancy has been ruled out.

Drug interactions

There is little information on the clinical importance of drug interactions with MA. That said, mifepristone is metabolized by the CYP (cytochrome P450) 3A4 enzyme, and CYP 3A4 inducers such as phenytoin, rifampin, or St John’s wort might decrease the effectiveness of MA, leading to a higher likelihood of treatment failure. Inhibitors such as ketoconazole and grapefruit juice might increase the mifepristone side effects such as nausea. Food and antacids can decrease the bioavailability of oral misoprostol, but this should have little effect if it is administered by the buccal or vaginal route.

Patient education

Patients should know what to expect when they complete MA at home. Some patients can have bleeding after taking the mifepristone (step 1) but many do not feel anything at all. By comparison, within 3 hours of taking misoprostol (step 2), patients should expect bleeding heavier than menses. Patients should seek urgent care if they are soaking 2 sanitary pads per hour for more than 2 hours; if they are passing lemonsized tissues for more than 2 hours; or if the pain is unbearable or not improving with medication. Patients who do not have bleeding after misoprostol likely had either a treatment failure or are retaining the products of conception. Patients should be counseled on the potential for failure with MA and the potential need for a dilation and curettage procedure. Light bleeding can last an average of 2 weeks after MA, and only sanitary napkins should be used, not tampons or menstrual cups.

Cramps are often painful and patients can find relief from over-the-counter nonsteroidal anti-inflammatory drugs such as ibuprofen or naproxen. Some patients might also benefit from having a few doses of a prescription opioid. Some individuals might prefer to take the misoprostol in the evening to avoid heavy cramping during the daytime hours.

Misoprostol can cause nausea, diarrhea, dizziness, fever, and headaches within 2 to 4 hours of administration. Loperamide and dimenhydrinate can be recommended for symptom control. A fever of 38°C (100.4°F) or higher, and nausea, vomiting, diarrhea, dizziness, or weakness occurring more than 24 hours after misoprostol administration require emergency assessment for infection or toxic shock syndrome.

Finally, it is crucial that practitioners inquire about future contraception, as ovulation can occur 8 days after MA, and counsel on available contraception and pregnancy options. For example, hormonal contraceptive pills or the patch can be started when misoprostol is taken, or an intrauterine device can be inserted at the follow-up visit after MA.

Conclusion

Primary care practitioners are well positioned to provide patients with education and access to MA. The next time your patient requests MA, remember to educate them on what to expect, assess for contraindications, and plan for future contraception and follow-up.

Acknowledgments

We thank Adrian Poon for designing the infographic, as well as Dr Judith Soon, Dr Nese Yuksel, Dr Sheila Dunn, and Ms Kayla Orr for providing their expert feedback in creating the infographic. This work was supported in part by the Ontario College of Pharmacists through funding in support of the Pharmacy5in5 program.

Notes

We encourage readers to share some of their practice experience: the neat little tricks that solve difficult clinical situations. Praxis articles can be submitted online at http://mc.manuscriptcentral.com/cfp or through the CFP website (www.cfp.ca) under “Authors and Reviewers.”

Footnotes

  • ↵* The infographic on medical abortion (Figure 1) is available at www.cfp.ca. Go to the full text of the article online and click on the CFPlus tab.

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Norman WV
    . Induced abortion in Canada 1974–2005: trends over the first generation with legal access. Contraception 2012;85(2):185-91. Epub 2011 Aug 4.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Government of Canada [website].
    Recalls and safety alerts. Mifegymiso (mifepristone and misoprostol tablets)—updates to product monograph and risk management plan. Ottawa, ON: Government of Canada; 2017. Available from: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65030a-eng.php. Accessed 2019 Dec 3.
  3. 3.↵
    1. Costescu D,
    2. Guilbert E,
    3. Bernardin J,
    4. Black A,
    5. Dunn S,
    6. Fitzsimmons B,
    7. et al
    . Medical abortion. J Obstet Gynaecol Can 2016;38(4):366-89. Epub 2016 Apr 23. Erratum in: J Obstet Gynaecol Can 2017;39(1):67.
    OpenUrl
  4. 4.↵
    1. Soon JA,
    2. Costescu D,
    3. Guilbert E
    . Medications used in evidence-based regimens for medical abortion: an overview. J Obstet Gynaecol Can 2016;38(7):636-45. Epub 2016 May 14.
    OpenUrl
  5. 5.↵
    1. Canadian Pharmacists Association.
    , editor. Medical abortion. Compendium of therapeutics for minor ailments. Ottawa, ON: Canadian Pharmacists Association; 2018. Available from: www.myrxtx.ca. Accessed 2018 Aug 2.
  6. 6.↵
    1. Cable EE,
    2. Pepe JA,
    3. Donohue SE,
    4. Lambrecht RW,
    5. Bonkovsky HL
    . Effects of mifepristone (RU-486) on heme metabolism and cytochromes P-450 in cultured chick embryo liver cells, possible implications for acute porphyria. Eur J Biochem 1994;225(2):651-7.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 66 (1)
Canadian Family Physician
Vol. 66, Issue 1
1 Jan 2020
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Update on medical abortion
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Update on medical abortion
Ashley Bancsi, Kelly Grindrod
Canadian Family Physician Jan 2020, 66 (1) 42-44;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Update on medical abortion
Ashley Bancsi, Kelly Grindrod
Canadian Family Physician Jan 2020, 66 (1) 42-44;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • How to take MA medications
    • Prescribing MA
    • Contraindications to MA
    • Drug interactions
    • Patient education
    • Conclusion
    • Acknowledgments
    • Notes
    • Footnotes
    • References
  • Figures & Data
  • CFPlus
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • Google Scholar

Cited By...

  • Medical abortion is an essential service during the pandemic
  • Google Scholar

More in this TOC Section

Practice

  • Determining if and how older patients can safely stay at home with additional services
  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
Show more Practice

Praxis

  • Aide à la décision d’utiliser ou non les gliflozines pour l’insuffisance cardiaque avec fraction d’éjection supérieure à 40 %, à l’intention des patients
  • Patient decision aid for flozins in heart failure and ejection fraction greater than 40%
  • Examens et traitements à reconsidérer en médecine du sport et de l’exercice pédiatrique
Show more Praxis

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire